Baier Robert Edward
Biomaterials Graduate Program, State University of New York at Buffalo, NY 14214, USA.
J Mater Sci Mater Med. 2006 Nov;17(11):1057-62. doi: 10.1007/s10856-006-0444-8. Epub 2006 Nov 22.
"Biomaterials" are non-living substances selected to have predictable interactions with contacting biological phases, in applications ranging from medical/dental implants to food processing to control of biofouling in the sea. More than 30 years of empirical observations of the surface behaviours of various materials in biological settings, when correlated with the contact-angle-determined Critical Surface Tensions (CST) for these same materials, support the definition of the "theta surface". The "theta surface" is that characteristic expression of outermost atomic features least retentive of depositing proteins, and identified by the bioengineering criterion of having measured CST between 20 and 30 mN/m. Biomaterials applications requiring strong bioadhesion must avoid this range, while those requiring easy release of accumulating biomass should have "theta surface" qualities. Selection of blood-compatible materials is a main example. It is forecast that future biomaterials will be safely and effectively translated directly to clinical use, without requiring animal testing, based on laboratory data for CST, protein denaturation, and cell spreading alone.
“生物材料”是指被挑选出来的非生物物质,在从医学/牙科植入物到食品加工,再到控制海洋生物污垢等各种应用中,它们与接触的生物相具有可预测的相互作用。30多年来,对各种材料在生物环境中的表面行为进行的实证观察,与通过接触角测定的这些相同材料的临界表面张力(CST)相关联,支持了“θ表面”的定义。“θ表面”是最不易保留沉积蛋白质的最外层原子特征的特征性表现,通过测量CST在20至30 mN/m之间的生物工程标准来确定。需要强生物粘附性的生物材料应用必须避免这个范围,而那些需要容易释放积累生物量的应用则应具有“θ表面”特性。选择血液相容性材料就是一个主要例子。据预测,未来的生物材料将仅基于CST、蛋白质变性和细胞铺展的实验室数据,安全有效地直接转化为临床应用,而无需动物试验。